☰

Jeremy L. Baryza, Ph.D. - Publications

Affiliations: 
2005 Stanford University, Palo Alto, CA 
Area:
Organic, Organometallic, Bioorganic, and Medicinal Chemistry
Tree Info Similar researchers PubMed Report error

12/25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2011 Wender PA, Baryza JL, Brenner SE, DeChristopher BA, Loy BA, Schrier AJ, Verma VA. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proceedings of the National Academy of Sciences of the United States of America. 108: 6721-6. PMID 21415363 DOI: 10.1073/Pnas.1015270108  0.742
2009 Shaha SP, Tomic J, Shi Y, Pham T, Mero P, White D, He L, Baryza JL, Wender PA, Booth JW, Spaner DE. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clinical and Experimental Immunology. 158: 186-98. PMID 19737143 DOI: 10.1111/J.1365-2249.2009.04003.X  0.509
2006 Wender PA, Baryza JL, Hilinski MK, Horan JC, Kan C, Verma VA. Beyond Natural Products: Synthetic Analogues of Bryostatin 1 Drug Discovery Research: New Frontiers in the Post-Genomic Era. 125-162. DOI: 10.1002/9780470131862.ch6  0.712
2005 Statsuk AV, Bai R, Baryza JL, Verma VA, Hamel E, Wender PA, Kozmin SA. Actin is the primary cellular receptor of bistramide A. Nature Chemical Biology. 1: 383-8. PMID 16372404 DOI: 10.1038/Nchembio748  0.535
2005 Wender PA, Baryza JL. Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification. Organic Letters. 7: 1177-80. PMID 15760168 DOI: 10.1021/Ol0501931  0.496
2005 Hammond C, Shi Y, Mena J, Tomic J, Cervi D, He L, Millar AE, Debenedette M, Schuh AC, Baryza JL, Wender PA, Radvanyi L, Spaner DE. Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 28-39. PMID 15614042 DOI: 10.1097/00002371-200501000-00004  0.488
2004 Wender PA, Baryza JL, Brenner SE, Clarke MO, Craske ML, Horan JC, Meyer T. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Current Drug Discovery Technologies. 1: 1-11. PMID 16472215 DOI: 10.2174/1570163043484888  0.763
2004 Stone JC, Stang SL, Zheng Y, Dower NA, Brenner SE, Baryza JL, Wender PA. Synthetic bryostatin analogues activate the RasGRP1 signaling pathway. Journal of Medicinal Chemistry. 47: 6638-44. PMID 15588099 DOI: 10.1021/Jm0495069  0.67
2004 Baryza JL, Brenner SE, Craske ML, Meyer T, Wender PA. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP. Chemistry & Biology. 11: 1261-7. PMID 15380186 DOI: 10.1016/J.Chembiol.2004.06.014  0.704
2003 Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. Inspirations from nature. New reactions, new therapeutic leads, and new drug delivery systems Pure and Applied Chemistry. 75: 143-155. DOI: 10.1351/Pac200375020143  0.676
2003 Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. Inspirations from nature. New reactions, therapeutic leads, and drug delivery systems Pure and Applied Chemistry. 75: 143-155.  0.628
2002 Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacôte E, Lippa B, Nell PG, Turner TM. The practical synthesis of a novel and highly potent analogue of bryostatin. Journal of the American Chemical Society. 124: 13648-9. PMID 12431074 DOI: 10.1021/Ja027509+  0.682
Low-probability matches (unlikely to be authored by this person)
2004 Begley R, Liron T, Baryza J, Mochly-Rosen D. Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Biochemical and Biophysical Research Communications. 318: 949-54. PMID 15147964 DOI: 10.1016/J.Bbrc.2004.04.121  0.239
2016 Khosla C, Baryza J. Editorial overview: Next-generation therapeutics: Breaking new ground and making a difference for patients. Current Opinion in Chemical Biology. 32: 58-59. PMID 27206139 DOI: 10.1016/J.Cbpa.2016.04.017  0.221
2015 Wilson SC, Baryza JL, Reynolds AJ, Bowman K, Keegan ME, Standley SM, Gardner NP, Parmar P, Agir VO, Yadav S, Zunic A, Vargeese C, Lee CC, Rajan S. Real time measurement of PEG shedding from lipid nanoparticles in serum via NMR spectroscopy. Molecular Pharmaceutics. 12: 386-92. PMID 25581130 DOI: 10.1021/Mp500400K  0.17
2018 Müller S, Ackloo S, Arrowsmith CH, Bauser M, Baryza JL, Blagg J, Böttcher J, Bountra C, Brown PJ, Bunnage ME, Carter AJ, Damerell D, Dötsch V, Drewry DH, Edwards AM, et al. Donated chemical probes for open science. Elife. 7. PMID 29676732 DOI: 10.7554/Elife.34311  0.15
2010 Gaither LA, Borawski J, Anderson LJ, Balabanis KA, Devay P, Joberty G, Rau C, Schirle M, Bouwmeester T, Mickanin C, Zhao S, Vickers C, Lee L, Deng G, Baryza J, et al. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology. 397: 43-55. PMID 19932913 DOI: 10.1016/J.Virol.2009.10.043  0.141
2018 Mustoe AM, Busan S, Rice GM, Hajdin CE, Peterson BK, Ruda VM, Kubica N, Nutiu R, Baryza JL, Weeks KM. Pervasive Regulatory Functions of mRNA Structure Revealed by High-Resolution SHAPE Probing. Cell. PMID 29551268 DOI: 10.1016/J.Cell.2018.02.034  0.132
2015 Ma D, Tian S, Baryza J, Luft JC, DeSimone JM. Reductively Responsive Hydrogel Nanoparticles with Uniform Size, Shape, and Tunable Composition for Systemic siRNA Delivery in Vivo. Molecular Pharmaceutics. PMID 26287725 DOI: 10.1021/Acs.Molpharmaceut.5B00054  0.124
2006 Wood J, Bagi CM, Akuche C, Bacchiocchi A, Baryza J, Blue ML, Brennan C, Campbell AM, Choi S, Cook JH, Conrad P, Dixon BR, Ehrlich PP, Gane T, Gunn D, et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. Bioorganic & Medicinal Chemistry Letters. 16: 4965-8. PMID 16806919 DOI: 10.1016/j.bmcl.2006.06.041  0.113
2011 Matter Y, Enea R, Casse O, Lee CC, Baryza J, Meier W. Amphiphilic PEG-b- PMCL-b- PDMAEMA Triblock Copolymers: From Synthesis to Physico-Chemistry of Self-Assembled Structures Macromolecular Chemistry and Physics. 212: 937-949. DOI: 10.1002/MACP.201000661  0.087
2005 Gunn D, Akuche C, Baryza J, Blue ML, Brennan C, Campbell AM, Choi S, Cook J, Conrad P, Dixon B, Dumas J, Ehrlich P, Gane T, Joe T, Johnson J, et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR. Bioorganic & Medicinal Chemistry Letters. 15: 3053-7. PMID 15890515 DOI: 10.1016/j.bmcl.2005.04.025  0.068
2020 Rice GM, Shivashankar V, Ma EJ, Baryza JL, Nutiu R. Functional Atlas of Primary miRNA Maturation by the Microprocessor. Molecular Cell. PMID 33188727 DOI: 10.1016/j.molcel.2020.10.028  0.068
2014 Christensen J, Litherland K, Faller T, van de Kerkhof E, Natt F, Hunziker J, Boos J, Beuvink I, Bowman K, Baryza J, Beverly M, Vargeese C, Heudi O, Stoeckli M, Krauser J, et al. Biodistribution and metabolism studies of lipid nanoparticle-formulated internally [3H]-labeled siRNA in mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 431-40. PMID 24389421 DOI: 10.1124/dmd.113.055434  0.063
2009 Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, et al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. Journal of Virology. 83: 10058-74. PMID 19605471 DOI: 10.1128/Jvi.02418-08  0.047
Hide low-probability matches.